InsidersTradesSigma
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (2 ops.)
Explore the detailed record of transactions filed by KAKKIS EMIL D, Chief Executive Officer. Director active across 1 companies, notably Ultragenyx Pharmaceutical Inc.. In total, 7 filings have been recorded. Total volume traded: €5.4m. The latest transaction was filed on 1 March 2022 — Retenue fiscale. Regulator: SEC (Form 4). All data is free.
Declarations7 total
€730,52812,162 shares@ €60.06640.030% mcap11.5% of flow
Common Stock
SEC:0001209191-22-015799:0·
€59,607853 shares@ €69.87870.0024% mcap2.1% of flow
Common Stock
SEC:0001209191-21-060749·
€59,607853 shares@ €69.87870.0024% mcap0.9% of flow
Common Stock
SEC:0001209191-21-060749:0·
€81,687852 shares@ €95.87730.0033% mcap2.9% of flow
Common Stock
SEC:0001209191-21-031383·
€81,687852 shares@ €95.87730.0033% mcap1.3% of flow
Common Stock
SEC:0001209191-21-031383:0·
€3m30,000 shares@ €89.3770.11% mcap95.0% of flow
Common Stock
SEC:0001209191-21-030211·
€3m30,000 shares@ €89.3770.11% mcap42.1% of flow
Common Stock
SEC:0001209191-21-030211:0·
7 of 7 declarations
About KAKKIS EMIL D
Emil D. Kakkis serves as President and CEO at Ultragenyx Pharmaceutical Inc. In this role, he leads the strategic operations and business management of the company. His expertise in the pharmaceutical sector is essential to guide Ultragenyx towards innovation and growth.
